Gadolinium-Based Contrast Agents in Kidney Disease: Comprehensive Review and Clinical Practice Guideline Issued by the Canadian Association of Radiologists
Use of gadolinium-based contrast agents (GBCAs) in renal impairment is controversial, with physician and patient apprehension in acute kidney injury (AKI), chronic kidney disease (CKD), and dialysis because of concerns regarding nephrogenic systemic fibrosis (NSF). The position that GBCAs are absolutely contraindicated in AKI, CKD stage 4 or 5 (estimated glomerular filtration rate [eGFR]
Source: Canadian Association of Radiologists Journal - Category: Radiology Authors: Nicola Schieda, Jason I. Blaichman, Andreu F. Costa, Rafael Glikstein, Casey Hurrell, Matthew James, Pejman Jabehdar Maralani, Wael Shabana, An Tang, Anne Tsampalieros, Christian van der Pol, Swapnil Hiremath Tags: Magnetic Resonance Imaging / Formation image de r ésonance magnétique Source Type: research
More News: Canada Health | Chronic Kidney Disease | Dialysis | MRI Scan | Radiology | Urology & Nephrology